TLSITriSalus Life Sciences, Inc.

Nasdaq trisaluslifesci.com


$ 5.59 $ -0.25 (-4.3 %)    

Tuesday, 25-Jun-2024 15:59:52 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 5.57
$ 5.75
$ 0.00 x 0
$ 0.00 x 0
$ 5.52 - $ 5.81
$ 3.32 - $ 16.24
30,609
na
129.91M
$ 0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-11-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-02-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 06-28-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trisalus-life-sciences-presents-liver-and-pancreatic-cancer-data-at-asco-2024

TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) t...

 canaccord-genuity-initiates-coverage-on-trisalus-life-sciences-with-buy-rating-announces-price-target-of-12

Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and ...

 trisalus-life-sciences-q1-2024-gaap-eps-060-beats-065-estimate-sales-6457m-beat-6178m-estimate

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate o...

 jonestrading-initiates-coverage-on-trisalus-life-sciences-with-buy-rating-announces-price-target-of-16

JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces...

 trisalus-life-sciences-secures-up-to-50m-of-debt-financing-with-orbimed-to-support-trinav-infusion-system-growth-initiatives

$25 million funded at close; up to $25 million of additional capital available at the Company's option, based on the achiev...

 trisalus-life-sciences-q4-2023-gaap-eps-156-misses-069-estimate-sales-5721m-beat-5453m-estimate

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-april-1-2024

Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per...

 trisalus-life-sciences-expects-sales-to-grow-in-excess-of-50-in-2024-says-currently-in-the-process-of-obtaining-additional-liquidity-to-fund-operations-through-2024

TriSalus also expects to report cash and cash equivalents balances of approximately $11.8 million as of December 31, 2023. It e...

 trisalus-life-sciences-reports-preliminary-q4-sales-of-approximately-57m-representing-77-growth-versus-2022-est-5453m

For the full year 2023, TriSalus expects to report revenue of approximately $18.5 million. This represents growth of approximat...

 earnings-scheduled-for-november-14-2023

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...

 trisalus-life-sciences-q3-2023-eps-013-up-from-2595-yoy-sales-519m-up-from-392m-yoy

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.13) per share. This is a 99.5 percent increase over losse...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION